Carcinoma, Squamous Cell of Head and Neck
Conditions
Keywords
ctDNA
Brief summary
Tumours continually shed DNA into the circulation, where it can be accessed. This circulating tumour DNA (ctDNA) directly reflects tumour burden and has great potential to be a sensitive biomarker for treatment recurrence. These liquid biopsies could give a more real-time picture of the genomic status and evolution of a tumour and can be easily assessed for measurement of different biomarkers. However, in head and neck squamous cell carcinoma (HNSCC) patients treated with primary curative radiotherapy, data regarding ctDNA kinetics and its correlation with outcome are scarce. A new or additional tool for response evaluation next to or instead of conventional imaging after treatment would be beneficial to detect recurrences in an earlier stage, thereby increasing the chances of success of salvage therapy. More importantly, an early response parameter during treatment could help to identify patients that have a good treatment response and might benefit from treatment adaptation. With this study, we aim to reveal ctDNA as an effective tool for future dose (de)-escalation trials in HNSCC.
Interventions
OTHERBlood draw
Blood will be drawn to assess ctDNA
Sponsors
The Netherlands Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Prospective observational study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years of age * Stage II-IV carcinoma of the larynx, hypopharynx, oral cavity or HPV negative oropharynx or stage II-III HPV positive oropharyngeal carcinoma, histologically confirmed according to the American Joint Committee on Cancer (AJCC) staging manual 8th edition * Indication for primary curative radiotherapy with or without concurrent radio sensitizer * WHO performance status 0-2 * Signed written IC
Exclusion criteria
* Metastatic disease * Radiotherapy with palliative intent * Diagnosis of any other malignancy within 5 years prior to start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g. surgery, radiation or castration).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The number of patients in which ctDNA measurement (in amplifiable copies per millilitre blood and saliva) accurately predicts treatment outcome within 2 years after treatment, in terms of FFP. | 2 years | ctDNA biomarker |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Levels of ctDNA at the time of corresponding conventional imaging in relation to disease occurrence. | 3 years | ctDNA biomarker |
| The number of traceable mutations found in blood / saliva in comparison with mutations found in tissue biopsies. | 3 years | ctDNA biomarker |
| CtDNA kinetics (clearance time, drop below a certain level, complete absence, etc.) during radiotherapy as a predictor for disease recurrence within 2 years after treatment, in terms of FFP. | 2 years | ctDNA biomarker |
| Levels of ctDNA in blood compared to saliva at the same time points. | At study completion, after 3 years | ctDNA biomarker |
| Levels of ctDNA before treatment compared to other clinical/biological parameters in the prediction of treatment response. | 3 years | ctDNA biomarker |
| The tumours' genomic status and epigenetic evolution over time under pressure of radiotherapy, in terms of number of different detectable mutations at all specified time points. | 3 years | ctDNA biomarker |
Countries
Netherlands
Outcome results
None listed